Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 7Hodgkin Disease 6Lymphoma, Large B-Cell, Diffuse 5Triple Negative Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Rhabdomyosarcoma 3Lymphoma, Non-Hodgkin 3Leukemia 3Burkitt Lymphoma 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neuroblastoma 2Multiple Myeloma 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1Sleep Initiation and Maintenance Disorders 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Pancreatic Neoplasms 1Pain 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × pegfilgrastim × 1 year × Clear all
NCT01840566 2026-05-28

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡